$OPK
OPKO HEALTH, INC. Stock $opk

$opk Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000143774924015106 Filed on May 07, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2023 Q1
Revenue	$182.2M	$173.7M	$237.6M
YoY Change	-31.35%	-26.89%	-27.84%
Cost Of Revenue	$130.5M	$131.6M	$138.3M
YoY Change	-6.02%	-4.84%	-43.28%
Gross Profit	$51.65M	$42.07M	$99.26M
YoY Change	-59.17%	-57.62%	16.31%
Gross Profit Margin	28.35%	24.22%	41.78%
Selling, General & Admin	$68.82M	$70.17M	$75.64M
YoY Change	-13.76%	-7.24%	-35.64%
% of Gross Profit	133.24%	166.79%	76.2%
Research & Development	$24.08M	$21.94M	$32.61M
YoY Change	32.32%	-32.72%	78.05%
% of Gross Profit	46.62%	52.15%	32.85%
Depreciation & Amortization	$24.16M	$25.82M	$26.45M
YoY Change	12.35%	-2.37%	-4.92%
% of Gross Profit	46.76%	61.38%	26.64%
Operating Expenses	$243.9M	$245.2M	$268.2M
YoY Change	104.06%	-8.58%	-33.23%
Operating Profit	-$61.67M	-$71.47M	-$30.59M
YoY Change	-981.0%	133.61%	-57.76%
Interest Expense	-$7.788M	$7.686M	-$3.420M
YoY Change	-337.66%	-324.74%	22.84%
% of Operating Profit
Other Income/Expense, Net	$51.09M	-$11.71M	$13.60M
YoY Change	-317.39%	-186.13%	-421.75%
Pretax Income	-$10.58M	-$83.18M	-$17.00M
YoY Change	-35.85%	389.4%	-77.83%
Income Tax	-$280.0K	-$1.350M	$1.233M
% Of Pretax Income
Net Earnings	-$10.31M	-$81.84M	-$18.27M
YoY Change	-47.42%	348.0%	-67.05%
Net Earnings / Revenue	-5.66%	-47.12%	-7.69%
Basic Earnings Per Share	-$0.01	-$0.12	-$0.02
Diluted Earnings Per Share	-$0.01	-$0.12	-$0.02
COMMON SHARES
Basic Shares Outstanding	697.0M	697.0M	772.7M shares
Diluted Shares Outstanding			751.5M shares

Balance Sheet

Concept	2024 Q2	2024 Q1	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$40.58M	$67.39M	$110.8M
YoY Change	-62.46%	-39.19%	8.36%
Cash & Equivalents	$40.58M	$75.64M	$110.8M
Short-Term Investments
Other Short-Term Assets	$6.734M	$6.626M	$6.081M
YoY Change	-97.93%	8.96%	25.85%
Inventory	$60.15M	$59.37M	$75.41M
Prepaid Expenses
Receivables	$105.3M	$111.4M	$121.5M
Other Receivables	$10.70M	$7.839M	$81.92M
Total Short-Term Assets	$358.0M	$391.3M	$406.4M
YoY Change	-17.48%	-3.72%	-46.1%
LONG-TERM ASSETS
Property, Plant & Equipment	$66.77M	$64.17M	$117.7M
YoY Change	-15.35%	-45.48%	-5.6%
Goodwill	$530.1M	$530.6M	$597.4M
YoY Change	-11.26%	-11.18%	-15.91%
Intangibles	$659.1M	$680.0M
YoY Change	-15.74%
Long-Term Investments	$0.00	$0.00	$41.23M
YoY Change	-100.0%	-100.0%	335.29%
Other Assets	$7.796M	$8.578M	$8.340M
YoY Change	-99.16%	2.85%	-8.35%
Total Long-Term Assets	$1.622B	$1.583B	$1.763B
YoY Change	-5.98%	-10.24%	13.55%
TOTAL ASSETS
Total Short-Term Assets	$358.0M	$391.3M	$406.4M
Total Long-Term Assets	$1.622B	$1.583B	$1.763B
Total Assets	$1.980B	$1.974B	$2.170B
YoY Change	-8.29%	-9.02%	-5.95%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$82.24M	$71.16M	$80.50M
YoY Change	-6.44%	-11.61%	-14.58%
Accrued Expenses	$94.52M	$88.77M	$106.1M
YoY Change	-4.14%	-16.3%	-32.58%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.597M	$1.822M	$27.34M
YoY Change		-93.34%	37.64%
Total Short-Term Liabilities	$219.6M	$204.3M	$222.4M
YoY Change	-3.02%	-8.13%	-28.06%
LONG-TERM LIABILITIES
Long-Term Debt	$3.676M	$4.036M	$228.0M
YoY Change	-98.27%	-98.23%	5.39%
Other Long-Term Liabilities	$20.32M	$21.20M	$27.98M
YoY Change	-60.86%	-24.25%	78.69%
Total Long-Term Liabilities	$365.0M	$516.9M	$395.4M
YoY Change	38.15%	30.71%	3.3%
TOTAL LIABILITIES
Total Short-Term Liabilities	$219.6M	$204.3M	$222.4M
Total Long-Term Liabilities	$365.0M	$516.9M	$395.4M
Total Liabilities	$584.6M	$721.2M	$617.9M
YoY Change	-6.26%	16.73%	-10.71%
SHAREHOLDERS EQUITY
Retained Earnings	-$2.104B	-$2.094B	-$1.841B
YoY Change	13.06%	13.71%	18.79%
Common Stock	$7.273M	$7.269M	$7.813M
YoY Change	-6.96%	-6.96%	13.2%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.395B	$1.253B	$1.552B
YoY Change
Total Liabilities & Shareholders Equity	$1.980B	$1.974B	$2.170B
YoY Change	-8.29%	-9.02%	-5.95%

Cashflow Statement

Concept	2024 Q2	2024 Q1	2023 Q1
OPERATING ACTIVITIES
Net Income	-$10.31M	-$81.84M	-$18.27M
YoY Change	-47.42%	348.0%	-67.05%
Depreciation, Depletion And Amortization	$24.16M	$25.82M	$26.45M
YoY Change	12.35%	-2.37%	-4.92%
Cash From Operating Activities	-$26.43M	-$35.57M	-$22.65M
YoY Change	7142.47%	57.05%	14.06%
INVESTING ACTIVITIES
Capital Expenditures	$7.217M	$4.443M	$3.037M
YoY Change	20.02%	46.3%	-157.84%
Acquisitions
YoY Change
Other Investing Activities	$55.00K	$48.00K	-$4.680M
YoY Change	-89.46%	-101.03%	-1444.83%
Cash From Investing Activities	-$7.162M	-$4.395M	-$7.717M
YoY Change	30.43%	-43.05%	57.39%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-2.115M	$20.61M	-$13.12M
YoY Change	-161.09%	-257.12%	66.25%
NET CHANGE
Cash From Operating Activities	-26.43M	-$35.57M	-$22.65M
Cash From Investing Activities	-7.162M	-$4.395M	-$7.717M
Cash From Financing Activities	-2.115M	$20.61M	-$13.12M
Net Change In Cash	-35.71M	-$20.24M	-$42.36M
YoY Change	1391.73%	-52.22%	30.63%
FREE CASH FLOW
Cash From Operating Activities	-$26.43M	-$35.57M	-$22.65M
Capital Expenditures	$7.217M	$4.443M	$3.037M
Free Cash Flow	-$33.65M	-$40.01M	-$25.68M
YoY Change	427.63%	55.77%	75.86%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	dei	Amendment Flag AmendmentFlag	false
CY2024Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2024Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	726791854
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	781936885
CY2024Q1	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	29772753
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	8655082
CY2023Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	900000000	usd
CY2024Q1	us-gaap	Open Tax Year OpenTaxYear	2015 2016 2017 2018 2019 2020 2021
CY2024Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	pure
CY2024Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	pure
CY2024Q1	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2024#PropertyPlantAndEquipmentNet
CY2024Q1	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent
CY2024Q1	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent
CY2024Q1	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q1	dei	Document Type DocumentType	10-Q
CY2024Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2024Q1	dei	Document Period End Date DocumentPeriodEndDate	2024-03-31
CY2024Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2024Q1	dei	Entity File Number EntityFileNumber	001-33528
CY2024Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2024Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	75-2402409
CY2024Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	4400 Biscayne Blvd.
CY2024Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Miami
CY2024Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2024Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33137
CY2024Q1	dei	City Area Code CityAreaCode	305
CY2024Q1	dei	Local Phone Number LocalPhoneNumber	575-4100
CY2024Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.01 per share
CY2024Q1	dei	Trading Symbol TradingSymbol	OPK
CY2024Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2024Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2024Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024Q1	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	696991677
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	75639000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	95881000	usd
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	111367000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	123379000	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	59366000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	65697000	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	24652000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	24519000	usd
CY2024Q1	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	120279000	usd
CY2023Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	0	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	391303000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	309476000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	64165000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	75429000	usd
CY2024Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	680034000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	740283000	usd
CY2024Q1	opk	Capitalized Research And Development In Process CapitalizedResearchAndDevelopmentInProcess	195000000	usd
CY2023Q4	opk	Capitalized Research And Development In Process CapitalizedResearchAndDevelopmentInProcess	195000000	usd
CY2024Q1	us-gaap	Goodwill Goodwill	530615000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	598260000	usd
CY2024Q1	us-gaap	Long Term Investments LongTermInvestments	40990000	usd
CY2023Q4	us-gaap	Long Term Investments LongTermInvestments	16082000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	63331000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	68088000	usd
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	8578000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	9080000	usd
CY2024Q1	us-gaap	Assets Assets	1974016000	usd
CY2023Q4	us-gaap	Assets Assets	2011698000	usd
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	71157000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	69677000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	88772000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	90086000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	11742000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	12996000	usd
CY2024Q1	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	170000	usd
CY2023Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	0	usd
CY2024Q1	us-gaap	Loans Payable To Bank Current LoansPayableToBankCurrent	22820000	usd
CY2023Q4	us-gaap	Loans Payable To Bank Current LoansPayableToBankCurrent	27293000	usd
CY2024Q1	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	9677000	usd
CY2023Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	0	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	204338000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	200052000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	50931000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	54140000	usd
CY2024Q1	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	323108000	usd
CY2023Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	214325000	usd
CY2024Q1	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	121635000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	126773000	usd
CY2024Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	21196000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	27189000	usd
CY2024Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	516870000	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	422427000	usd
CY2024Q1	us-gaap	Liabilities Liabilities	721208000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	622479000	usd
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	7269000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	7820000	usd
CY2024Q1	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	1791000	usd
CY2023Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	1791000	usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	3386147000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	3433006000	usd
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-45195000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-38030000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2093622000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2011786000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	1252808000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	1389219000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1974016000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2011698000	usd
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	173686000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	237577000	usd
CY2024Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	70167000	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	75642000	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	21937000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	32605000	usd
CY2024Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	usd
CY2023Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	136000	usd
CY2024Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	21437000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	21474000	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	245158000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	268171000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-71472000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-30594000	usd
CY2024Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	813000	usd
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	1030000	usd
CY2024Q1	us-gaap	Interest Expense InterestExpense	7686000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	3391000	usd
CY2024Q1	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-26161000	usd
CY2023Q1	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-1059000	usd
CY2024Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	21323000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	17017000	usd
CY2024Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-11711000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	13597000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-83183000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-16997000	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1350000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1233000	usd
CY2024Q1	opk	Income Loss From Continuing Operations Net Of Tax Before Equity Method Investments And Noncontrolling Interest Total IncomeLossFromContinuingOperationsNetOfTaxBeforeEquityMethodInvestmentsAndNoncontrollingInterestTotal	-81833000	usd
CY2023Q1	opk	Income Loss From Continuing Operations Net Of Tax Before Equity Method Investments And Noncontrolling Interest Total IncomeLossFromContinuingOperationsNetOfTaxBeforeEquityMethodInvestmentsAndNoncontrollingInterestTotal	-18230000	usd
CY2024Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-3000	usd
CY2023Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-37000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-81836000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-18267000	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.12
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	706882189
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	751506257
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-81836000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-18267000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-7166000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	5712000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-89002000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-12555000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	1389219000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	0	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2590000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	usd
CY2024Q1	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	50000000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-81836000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-7165000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	1252808000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1561648000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2717000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-18267000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	5712000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	1551810000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-81836000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-18267000	usd
CY2024Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	25820000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	26446000	usd
CY2024Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	3843000	usd
CY2023Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	678000	usd
CY2024Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	519000	usd
CY2023Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	296000	usd
CY2024Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-3000	usd
CY2023Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-37000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2590000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2717000	usd
CY2024Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	47000	usd
CY2023Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-1845000	usd
CY2024Q1	opk	Changes In Fair Value Gain Loss In Equity Securities Fvni And Derivative Instruments ChangesInFairValueGainLossInEquitySecuritiesFvniAndDerivativeInstruments	-1251000	usd
CY2023Q1	opk	Changes In Fair Value Gain Loss In Equity Securities Fvni And Derivative Instruments ChangesInFairValueGainLossInEquitySecuritiesFvniAndDerivativeInstruments	7130000	usd
CY2024Q1	opk	Gain Loss On Conversion Of Debt GainLossOnConversionOfDebt	-757000	usd
CY2023Q1	opk	Gain Loss On Conversion Of Debt GainLossOnConversionOfDebt	-0	usd
CY2024Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	usd
CY2023Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	136000	usd
CY2024Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-2680000	usd
CY2023Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	102000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-9518000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-7364000	usd
CY2024Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-2274000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1306000	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	552000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	58902000	usd
CY2024Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-7000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-772000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2789000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	12759000	usd
CY2024Q1	opk	Increase Decrease In Foreign Currency Measurement IncreaseDecreaseInForeignCurrencyMeasurement	1225000	usd
CY2023Q1	opk	Increase Decrease In Foreign Currency Measurement IncreaseDecreaseInForeignCurrencyMeasurement	-2355000	usd
CY2024Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	usd
CY2023Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	2000	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-1047000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	9547000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-35566000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-22647000	usd
CY2024Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	-0	usd
CY2023Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	5000000	usd
CY2024Q1	us-gaap	Proceeds From Sale Of Equity Securities Fv Ni ProceedsFromSaleOfEquitySecuritiesFvNi	48000	usd
CY2023Q1	us-gaap	Proceeds From Sale Of Equity Securities Fv Ni ProceedsFromSaleOfEquitySecuritiesFvNi	320000	usd
CY2024Q1	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	4443000	usd
CY2023Q1	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	3037000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4395000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-7717000	usd
CY2024Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	230000000	usd
CY2023Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	usd
CY2024Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	8562000	usd
CY2023Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	-0	usd
CY2024Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	50000000	usd
CY2023Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	-0	usd
CY2024Q1	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	163703000	usd
CY2023Q1	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	165288000	usd
CY2024Q1	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	168241000	usd
CY2023Q1	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	175407000	usd
CY2024Q1	us-gaap	Repayments Of Senior Debt RepaymentsOfSeniorDebt	146287000	usd
CY2023Q1	us-gaap	Repayments Of Senior Debt RepaymentsOfSeniorDebt	3000000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	20613000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-13119000	usd
CY2024Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-894000	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1122000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-20242000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-42361000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	95881000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	153191000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	75639000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	110830000	usd
CY2024Q1	us-gaap	Interest Paid Net InterestPaidNet	3125000	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	3830000	usd
CY2024Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1063000	usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	477000	usd
CY2024Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	0	usd
CY2023Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	960000	usd
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	41800000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	34600000	usd
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;"><i>Use of estimates</i>. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ significantly from these estimates.</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;"></p>
CY2024Q1	us-gaap	Inventory Write Down InventoryWriteDown	400000	usd
CY2023Q1	us-gaap	Inventory Write Down InventoryWriteDown	1400000	usd
CY2024Q1	opk	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Goodwill And Intangible Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwillAndIntangibleAssets	1400000000	usd
CY2023Q4	opk	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Goodwill And Intangible Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwillAndIntangibleAssets	1500000000	usd
CY2024Q1	us-gaap	Goodwill Goodwill	530600000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	598300000	usd
CY2024Q1	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	900000000	usd
CY2024Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	21400000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	21500000	usd
CY2024Q1	us-gaap	Depreciation Depreciation	4400000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	5000000	usd
CY2024Q1	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2024Q1	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	9900000	usd
CY2024Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;"><i>Concentration of credit risk and allowance for credit losses</i>. Financial instruments that potentially subject us to concentrations of credit risk consist primarily of accounts receivable. Substantially all of our accounts receivable are with either companies in the healthcare industry or patients. However, credit risk is limited due to the number of our clients as well as their dispersion across many different geographic regions.</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">While we have receivables due from federal and state governmental agencies, such receivables are <em style="font: inherit;">not</em> a credit risk because federal and state governments fund the related healthcare programs. Payment is primarily dependent upon submitting appropriate documentation. On <em style="font: inherit;"> March 31, 2024</em> and <em style="font: inherit;"> December 31, 2023</em>, receivable balances (net of explicit and implicit price concessions) from Medicare and Medicaid were 7.4% and 6.7%, respectively, of our consolidated Accounts receivable, net. The portion of our accounts receivable due from individual patients comprises the largest portion of credit risk. At <em style="font: inherit;"> March 31, 2024</em> and <em style="font: inherit;"> December 31, 2023</em>, receivables due from patients represented approximately 2.2% and 2.0%, respectively, of our consolidated Accounts receivable, net.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">We assess the collectability of accounts receivable balances by considering factors such as historical collection experience, customer credit worthiness, the age of accounts receivable balances, regulatory changes and current economic conditions and trends that <em style="font: inherit;"> may </em>affect a customer’s ability to pay. Actual results could differ from those estimates. The allowance for credit losses was $2.0 million on each of <em style="font: inherit;"> March 31, 2024</em>, and <em style="font: inherit;"> December 31, 2023</em>. The credit loss expense for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2024</em> and <em style="font: inherit;">2023,</em> was $128.6 thousand and $85.2 thousand, respectively.</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">As of <em style="font: inherit;"> March 31, 2024, </em>accounts receivable included $0.8 million of revenue earned under the BARDA Contract (as defined in Note <em style="font: inherit;">14</em>). As of <em style="font: inherit;"> December 31, 2023, </em>accounts receivable included $0.6 million under this contract. Refer to Note <em style="font: inherit;">13,</em> Government Contract Revenue for further information on government contracts and to Note <em style="font: inherit;">14,</em> Strategic Alliances for further information on the BARDA Contract.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;"></p>
CY2024Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	2000000	usd
CY2024Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	128600	usd
CY2023Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	85200	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2600000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2700000	usd
CY2024Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-2700000	usd
CY2023Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	1000000	usd
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	296587793
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	82441440
CY2024Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2024Q1	us-gaap	Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures	0
CY2024Q1	us-gaap	Stock Issued During Period Shares Share Based Compensation StockIssuedDuringPeriodSharesShareBasedCompensation	0
CY2023Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2023Q1	us-gaap	Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures	0
CY2023Q1	us-gaap	Stock Issued During Period Shares Share Based Compensation StockIssuedDuringPeriodSharesShareBasedCompensation	0
CY2024Q1	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	113360000	usd
CY2023Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	125379000	usd
CY2024Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1993000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	2000000	usd
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	111367000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	123379000	usd
CY2024Q1	us-gaap	Other Inventory Supplies OtherInventorySupplies	19346000	usd
CY2023Q4	us-gaap	Other Inventory Supplies OtherInventorySupplies	35582000	usd
CY2024Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	34008000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	25864000	usd
CY2024Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	3286000	usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	1731000	usd
CY2024Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	8246000	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	8981000	usd
CY2024Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	5520000	usd
CY2023Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	6461000	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	59366000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	65697000	usd
CY2024Q1	us-gaap	Prepaid Taxes PrepaidTaxes	3674000	usd
CY2023Q4	us-gaap	Prepaid Taxes PrepaidTaxes	4211000	usd
CY2024Q1	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	8649000	usd
CY2023Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	6177000	usd
CY2024Q1	us-gaap	Prepaid Insurance PrepaidInsurance	1538000	usd
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	3848000	usd
CY2024Q1	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	4165000	usd
CY2023Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	2610000	usd
CY2024Q1	us-gaap	Other Assets Current OtherAssetsCurrent	6626000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	7673000	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	24652000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	24519000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	471072000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	488694000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	680034000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	740283000	usd
CY2024Q1	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	31264000	usd
CY2023Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	28952000	usd
CY2024Q1	opk	Accrued Clinical Trials AccruedClinicalTrials	6077000	usd
CY2023Q4	opk	Accrued Clinical Trials AccruedClinicalTrials	7624000	usd
CY2024Q1	opk	Accrued Commitments And Contingencies Current AccruedCommitmentsAndContingenciesCurrent	8642000	usd
CY2023Q4	opk	Accrued Commitments And Contingencies Current AccruedCommitmentsAndContingenciesCurrent	8088000	usd
CY2024Q1	opk	Accrued Gross To Net Provision AccruedGrossToNetProvision	6082000	usd
CY2023Q4	opk	Accrued Gross To Net Provision AccruedGrossToNetProvision	9420000	usd
CY2024Q1	opk	Accrued Inventory Not Yet Billed AccruedInventoryNotYetBilled	2972000	usd
CY2023Q4	opk	Accrued Inventory Not Yet Billed AccruedInventoryNotYetBilled	1653000	usd
CY2024Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	1783000	usd
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	2827000	usd
CY2024Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2571000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3470000	usd
CY2024Q1	us-gaap	Taxes Payable Current TaxesPayableCurrent	3751000	usd
CY2023Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	1384000	usd
CY2024Q1	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	1705000	usd
CY2023Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	1544000	usd
CY2024Q1	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	1877000	usd
CY2023Q4	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	1822000	usd
CY2024Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	22048000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	23302000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	88772000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	90086000	usd
CY2024Q1	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	4036000	usd
CY2023Q4	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	7709000	usd
CY2024Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	4987000	usd
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	7274000	usd
CY2024Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	7000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	7000	usd
CY2024Q1	us-gaap	Other Liabilities And Deferred Revenue Noncurrent OtherLiabilitiesAndDeferredRevenueNoncurrent	12166000	usd
CY2023Q4	us-gaap	Other Liabilities And Deferred Revenue Noncurrent OtherLiabilitiesAndDeferredRevenueNoncurrent	12199000	usd
CY2024Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	21196000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	27189000	usd
CY2023Q4	us-gaap	Goodwill Gross GoodwillGross	636283000	usd
CY2024Q1	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	38023000	usd
CY2024Q1	opk	Goodwill Acquired Disposed Of During Period GoodwillAcquiredDisposedOfDuringPeriod	-65294000	usd
CY2024Q1	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-2351000	usd
CY2024Q1	us-gaap	Goodwill Goodwill	530615000	usd
CY2024Q1	us-gaap	Equity Method Investments EquityMethodInvestments	-0	usd
CY2024Q1	us-gaap	Equity Method Investment Underlying Equity In Net Assets EquityMethodInvestmentUnderlyingEquityInNetAssets	2734000	usd
CY2023Q4	us-gaap	Equity Method Investments EquityMethodInvestments	-0	usd
CY2023Q4	us-gaap	Equity Method Investment Underlying Equity In Net Assets EquityMethodInvestmentUnderlyingEquityInNetAssets	2942000	usd
CY2024Q1	opk	Equity Method Investment Variable Interest Entity EquityMethodInvestmentVariableInterestEntity	793000	usd
CY2024Q1	opk	Equity Method Investment Variable Interest Entity Underlying Equity In Net Assets EquityMethodInvestmentVariableInterestEntityUnderlyingEquityInNetAssets	157000	usd
CY2023Q4	opk	Equity Method Investment Variable Interest Entity EquityMethodInvestmentVariableInterestEntity	796000	usd
CY2023Q4	opk	Equity Method Investment Variable Interest Entity Underlying Equity In Net Assets EquityMethodInvestmentVariableInterestEntityUnderlyingEquityInNetAssets	420000	usd
CY2024Q1	us-gaap	Equity Method Investments Fair Value Disclosure EquityMethodInvestmentsFairValueDisclosure	32490000	usd
CY2023Q4	us-gaap	Equity Method Investments Fair Value Disclosure EquityMethodInvestmentsFairValueDisclosure	9786000	usd
CY2024Q1	us-gaap	Equity Securities Fv Ni Current And Noncurrent EquitySecuritiesFvNiCurrentAndNoncurrent	183000	usd
CY2023Q4	us-gaap	Equity Securities Fv Ni Current And Noncurrent EquitySecuritiesFvNiCurrentAndNoncurrent	116000	usd
CY2024Q1	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	7521000	usd
CY2023Q4	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	5382000	usd
CY2024Q1	opk	Equity Investments Carrying Value Of Equity Intruments EquityInvestmentsCarryingValueOfEquityIntruments	3000	usd
CY2023Q4	opk	Equity Investments Carrying Value Of Equity Intruments EquityInvestmentsCarryingValueOfEquityIntruments	2000	usd
CY2024Q1	us-gaap	Long Term Investments LongTermInvestments	40990000	usd
CY2023Q4	us-gaap	Long Term Investments LongTermInvestments	16082000	usd
CY2024Q1	us-gaap	Equity Method Investment Quoted Market Value EquityMethodInvestmentQuotedMarketValue	600000	usd
CY2023Q4	us-gaap	Equity Method Investment Quoted Market Value EquityMethodInvestmentQuotedMarketValue	700000	usd
CY2024Q1	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	67000	usd
CY2023Q1	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-105000	usd
CY2024Q1	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	67000	usd
CY2023Q1	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-105000	usd
CY2024Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	1822000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	1992000	usd
CY2024Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	4036000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	7727000	usd
CY2024Q1	us-gaap	Long Term Debt LongTermDebt	350134000	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	249345000	usd
CY2024Q1	us-gaap	Long Term Debt LongTermDebt	350134000	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	249345000	usd
CY2024Q1	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	50000000	usd
CY2024Q1	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	0.9067
CY2024Q1	us-gaap	Line Of Credit Facility Interest Rate At Period End LineOfCreditFacilityInterestRateAtPeriodEnd		pure
CY2024Q1	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	79880000	usd
CY2024Q1	us-gaap	Line Of Credit LineOfCredit	20998000	usd
CY2023Q4	us-gaap	Line Of Credit LineOfCredit	25300000	usd
CY2019Q3	us-gaap	Area Of Real Estate Property AreaOfRealEstateProperty	29500
CY2019Q3	opk	Operating Leases Monthly Payments Year One OperatingLeasesMonthlyPaymentsYearOne	89000	usd
CY2019Q3	opk	Operating Leases Monthly Payments Year Five OperatingLeasesMonthlyPaymentsYearFive	101000	usd
CY2024Q1	us-gaap	Purchase Obligation PurchaseObligation	46500000	usd
CY2024Q1	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	500000	usd
CY2023Q1	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	4800000	usd
CY2024Q1	opk	Accrued Expense Payor Overpayment Reimbursement Liability AccruedExpensePayorOverpaymentReimbursementLiability	4700000	usd
CY2023Q4	opk	Accrued Expense Payor Overpayment Reimbursement Liability AccruedExpensePayorOverpaymentReimbursementLiability	3100000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-71472000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-30594000	usd
CY2024Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	25820000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	26446000	usd
CY2024Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	-3000	usd
CY2023Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	-37000	usd
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	173686000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	237577000	usd
CY2024Q1	us-gaap	Assets Assets	1974016000	usd
CY2023Q4	us-gaap	Assets Assets	2011698000	usd
CY2024Q1	us-gaap	Goodwill Goodwill	530615000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	598260000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	63331000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	68088000	usd
CY2024Q1	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	6770	usd
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	10101	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	11742000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	12996000	usd
CY2024Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	1783000	usd
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	2827000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	50931000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	54140000	usd
CY2024Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	4987000	usd
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	7274000	usd
CY2024Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y2M12D
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y1M6D
CY2024Q1	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P7Y7M6D
CY2023Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P6Y2M12D
CY2024Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.054	pure
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.054	pure
CY2024Q1	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.023	pure
CY2023Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.038	pure
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	9353000	usd
CY2024Q1	us-gaap	Finance Lease Liability Payments Remainder Of Fiscal Year FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear	1630000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	11065000	usd
CY2024Q1	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	1500000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	10228000	usd
CY2024Q1	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	1206000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	10130000	usd
CY2024Q1	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	514000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	9957000	usd
CY2024Q1	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	194000	usd
CY2024Q1	opk	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	25763000	usd
CY2024Q1	opk	Finance Lease Liability Payments Due After Year Four FinanceLeaseLiabilityPaymentsDueAfterYearFour	1880000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	76496000	usd
CY2024Q1	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	6924000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	13823000	usd
CY2024Q1	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	154000	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	62673000	usd
CY2024Q1	us-gaap	Finance Lease Liability FinanceLeaseLiability	6770000	usd
CY2024Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	4400000	usd
CY2024Q1	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	600000	usd
CY2024Q1	us-gaap	Variable Lease Cost VariableLeaseCost	500000	usd
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	4100000	usd
CY2023Q1	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	700000	usd
CY2023Q1	us-gaap	Variable Lease Cost VariableLeaseCost	700000	usd
CY2024Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	4332000	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	3872000	usd
CY2024Q1	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	134000	usd
CY2023Q1	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	108000	usd
CY2024Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	640000	usd
CY2023Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	656000	usd
CY2024Q1	opk	Payments For Leases PaymentsForLeases	5106000	usd
CY2023Q1	opk	Payments For Leases PaymentsForLeases	4636000	usd

Files In Submission

Name	View Source	Status
0001437749-24-015106-index-headers.html	Edgar Link	pending
0001437749-24-015106-index.html	Edgar Link	pending
0001437749-24-015106.txt	Edgar Link	pending
0001437749-24-015106-xbrl.zip	Edgar Link	pending
ex_638079.htm	Edgar Link	pending
ex_638080.htm	Edgar Link	pending
ex_638081.htm	Edgar Link	pending
ex_638082.htm	Edgar Link	pending
ex_667413.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
opk-20240331.xsd	Edgar Link	pending
opk20240331c_10q.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
opk-20240331_cal.xml	Edgar Link	unprocessable
opk-20240331_lab.xml	Edgar Link	unprocessable
opk-20240331_def.xml	Edgar Link	unprocessable
opk-20240331_pre.xml	Edgar Link	unprocessable
opk20240331c_10q_htm.xml	Edgar Link	completed
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$OPK
OPKO HEALTH, INC. Stock $opk

2024 Q2 Form 10-Q Financial Statement

#000143774924015106 Filed on May 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OPK OPKO HEALTH, INC. Stock $opk

2024 Q2 Form 10-Q Financial Statement

#000143774924015106 Filed on May 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OPK
OPKO HEALTH, INC. Stock $opk